Security record · archived quarter
BIIB
Biogen Inc. · Healthcare · Drug Manufacturers - General
3Tracked holders
-1Δ holders
75.75KShares held
$11.04MReported value
+0New positions
−2Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 75.75K | $11.04M | n/a | −2 |
| Q2 2026 | 159 | 0 | 117.81M | $25.44B | +6 | −7 |
| Q1 2026 | 163 | -1 | 110.78M | $20.30B | +4 | −6 |
| Q4 2025 | 163 | 0 | 123.15M | $21.67B | +2 | −1 |
| Q3 2025 | 24 | +1 | 81.72M | $11.44B | +1 | −1 |
| Q2 2025 | 21 | 0 | 78.50M | $9.86B | n/a | n/a |
| Q1 2025 | 18 | +2 | 41.87M | $5.73B | +3 | −1 |
| Q4 2024 | 16 | -1 | 41.64M | $6.37B | n/a | −1 |
| Q3 2024 | 16 | +2 | 32.39M | $6.28B | +2 | n/a |
| Q2 2024 | 14 | n/a | 30.72M | $7.12B | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 65.65K | -2.5% | $8.76M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 9.47K | -17.9% | $2.14M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 634 | -8.1% | $141,404 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Robeco Institutional Asset… | $170.92M | was 0.2% |
| Ninety One UK Ltd | $40,620 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 995 holders, 132.27M shares, $23.30B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 06
SC 13G/A: FMR LLC
Jun 05
SC 13G/A: FMR LLC
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API